ValiRx (VAL) Share Price, News & Analysis

Company Overview

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.

Key Stats

• Today's Range: 1.60 to 1.90
• 50-Day Range: 1.81 to 2.90
• 52-Week Range: 1.60 to 15
• Volume: 2.49 million shs
• Average Volume: 1.05 million shs
• Market Capitalization: £2.18 million
• P/E Ratio: N/A
• Dividend Yield: 0.63%
• Price Target: N/A
• Consensus Rating: N/A

VAL Stock Analysis - Frequently Asked Questions

How have VAL shares performed this year?

ValiRx's stock was trading at GBX 5.90 at the beginning of the year. Since then, VAL stock has decreased by 72.0% and is now trading at GBX 1.65.
View the best growth stocks for 2024 here.

How were ValiRx's earnings last quarter?

ValiRx plc (LON:VAL) issued its quarterly earnings results on Monday, September, 7th. The company reported ($4.43) earnings per share (EPS) for the quarter.

How do I buy shares of ValiRx?

Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of ValiRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Scirocco Energy Plc (SOLO.L) (SOLO), CyanConnode (CYAN) and IQE (IQE).

Company Calendar

• Last Earnings: 9/07/2020
• Today: 9/18/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Petroleum And Natural Gas
• Current Symbol: LON:VAL
• CUSIP: N/A
• CIK: N/A
• Web: www.valirx.com
• Phone: +44-20-30084416
• Fax: N/A
• Employees: 5,450
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-2,040,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -63.23%
• Return on Assets: -40.43%

Debt

• Debt-to-Equity Ratio: 0.76
• Current Ratio: 2.64
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: GBX 0.03 per share
• Price / Cash Flow: 62.50
• Book Value: GBX 3 per share
• Price / Book: 0.57

Miscellaneous

• Outstanding Shares: 132,350,000
• Free Float: N/A
• Market Cap: £2.25 million
• Optionable: Not Optionable
• Beta: 0.59